Loading
Loading
Research Overview
Soluble ACVR2B-Fc fusion protein acting as a decoy receptor; binds myostatin (GDF-8), activins, and GDF-11, preventing their activation of endogenous ACVR2B on skeletal muscle cells and removing the braking signal on muscle hypertrophy.
Overview
ACE-031 was developed by Acceleron Pharma as a therapeutic candidate for muscle-wasting diseases including Duchenne muscular dystrophy. Its mechanism involves competitive inhibition of myostatin — a TGF-β superfamily ligand that limits muscle growth — by acting as a soluble decoy receptor that 'traps' myostatin and related ligands before they can bind to endogenous ACVR2B on muscle cell surfaces.
Phase 1 clinical trials in healthy postmenopausal women demonstrated significant lean mass increases within weeks of administration, validating the myostatin-inhibition hypothesis. However, Phase 2 development in Duchenne patients was halted in 2013 following adverse events including epistaxis (nosebleeds) and telangiectasias, attributed to off-target inhibition of non-myostatin TGF-β ligands with vascular roles.
ACE-031 differs from other myostatin-targeting approaches by blocking multiple TGF-β superfamily ligands simultaneously — not only myostatin but also activins and GDF-11 — which contributes both to its potent muscle-promoting effects and its safety signal liability.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, ace-031 (acvr2b-fc) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Soluble ACVR2B-Fc fusion protein acting as a decoy receptor; binds myostatin (GDF-8), activins, and GDF-11, preventing their activation of endogenous ACVR2B on skeletal muscle cells and removing the braking signal on muscle hypertrophy.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.